Complete Filing Data
Unicycive Therapeutics, Inc. reported Stockholders Equity of $30.20 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Unicycive Therapeutics, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income * | -$26.6M | -$36.7M | -$30.5M | -$18.1M | -$10.0M | -$2.3M |
| Research And Development Expense | $9.1M | $20.0M | $12.9M | $12.4M | $6.1M | $1.0M |
| Operating Expenses | $29.5M | $32.1M | $21.4M | $19.0M | $9.0M | $2.0M |
| General And Administrative Expense | $20.4M | $12.1M | $8.5M | $6.6M | $2.9M | $1.0M |
| Operating Income Loss | -$29.5M | -$32.1M | -$20.8M | -$18.1M | -$9.0M | -$2.0M |
| Nonoperating Income Expense | $3.0M | -$4.6M | -$9.8M | -$6.0K | -$1.0M | -$244.0K |
| Net Income Loss Available To Common Stockholders Basic | -$26.6M | -$37.8M | -$31.4M | -$18.1M | ||
| Interest Expense | $82.0K | $6.0K | $628.0K | $244.0K | ||
| Interest Expense Nonoperating | $71.0K | $71.0K | $82.0K | |||
| Revenues | $675.0K | $951.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$6.0M | -$6.4M | $570.0K | -$4.1M | $9.9M | -$21.0M | -$4.3M | -$3.8M | -$14.6M | -$5.6M | -$3.6M | -$3.5M | -$5.2M | -$1.1M | -$964.0K | -$702.0K | -$338.0K | -$344.0K |
| Research And Development Expense | $3.0M | $1.8M | $2.2M | $3.0M | $4.9M | $6.8M | $3.4M | $2.3M | $3.0M | $4.8M | $1.9M | $1.9M | $3.8M | $493.0K | $450.0K | $304.0K | $182.0K | |
| Operating Expenses | $7.3M | $7.0M | $8.0M | $6.3M | $7.4M | $9.2M | $5.9M | $4.3M | $4.9M | $6.5M | $3.6M | $3.5M | $4.7M | $779.0K | $731.0K | $626.0K | $336.0K | |
| General And Administrative Expense | $4.4M | $5.2M | $5.8M | $3.2M | $2.5M | $2.4M | $2.6M | $2.1M | $1.8M | $1.7M | $1.8M | $1.6M | $939.0K | $286.0K | $281.0K | $322.0K | $154.0K | |
| Operating Income Loss | -$7.3M | -$7.0M | -$8.0M | -$6.3M | -$7.4M | -$9.2M | -$5.9M | -$4.3M | -$4.2M | -$5.6M | -$3.6M | -$3.5M | -$4.7M | -$779.0K | -$731.0K | -$626.0K | -$336.0K | |
| Nonoperating Income Expense | $1.3M | $516.0K | $8.6M | $2.2M | $17.3M | -$11.8M | $1.6M | $484.0K | -$10.4M | -$3.0K | -$486.0K | -$321.0K | -$233.0K | -$76.0K | -$2.0K | |||
| Net Income Loss Available To Common Stockholders Basic | -$6.0M | -$6.4M | $510.0K | -$4.1M | $3.0M | -$21.2M | -$4.4M | -$4.4M | -$14.8M | -$5.6M | -$3.6M | -$3.5M | ||||||
| Interest Expense | $20.0K | $18.0K | $32.0K | $12.0K | $3.0K | $55.0K | $321.0K | $252.0K | $76.0K | $2.0K | ||||||||
| Interest Expense Nonoperating | $15.0K | $13.0K | $15.0K | $15.0K | $16.0K | $20.0K | $18.0K | $32.0K | ||||||||||
| Revenues | $675.0K | $951.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Stockholders Equity | $30.2M | $7.4M | -$3.8M | -$466.0K | $16.5M | -$2.7M | -$884.0K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $29.2M | $26.1M | $9.7M | $455.0K | $16.6M | $15.0K | |
| Retained Earnings Accumulated Deficit | -$127.8M | -$101.3M | -$64.5M | -$34.0M | -$15.9M | -$5.9M | |
| Liabilities Current | $18.9M | $24.1M | $17.5M | $3.3M | $2.1M | $2.9M | |
| Liabilities And Stockholders Equity | $49.1M | $31.7M | $14.2M | $2.8M | $18.7M | $204.0K | |
| Liabilities | $18.9M | $24.2M | $18.0M | $3.3M | $2.3M | $2.9M | |
| Common Stock Value | $22.0K | $11.0K | $35.0K | $15.0K | $15.0K | $9.0K | |
| Assets Current | $49.0M | $30.9M | $13.4M | $2.6M | $18.4M | $204.0K | |
| Assets | $49.1M | $31.7M | $14.2M | $2.8M | $18.7M | $204.0K | |
| Accounts Payable Current | $383.0K | $1.1M | $839.0K | $892.0K | $742.0K | $184.0K | |
| Accrued Liabilities Current | $1.5M | $3.6M | $3.2M | $2.2M | $1.2M | ||
| Property Plant And Equipment Net | $66.0K | $75.0K | $26.0K | $22.0K | $28.0K | ||
| Operating Lease Right Of Use Asset | $108.0K | $645.0K | $766.0K | $152.0K | $305.0K | ||
| Operating Lease Liability Current | $117.0K | $564.0K | $327.0K | $155.0K | $151.0K | ||
| Operating Lease Right Of Use Asset Amortization Expense | $538.0K | $406.0K | $275.0K | $154.0K | $12.0K | ||
| Prepaid Expense And Other Assets Current | $7.7M | $4.8M | $3.7M | $2.2M | $1.8M | $4.0K | |
| Cash And Cash Equivalents At Carrying Value | $29.2M | $26.1M | $16.6M | ||||
| Operating Lease Liability Noncurrent | $117.0K | $466.0K | $155.0K | ||||
| Deferred Insurance Charges Included In Prepaid Expenses And Other Current Assets | $332.0K | $267.0K | $270.0K | $240.0K | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | $3.1M | $16.4M | $9.2M | -$16.1M | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$16.1M | $16.6M | -$15.0K | ||||
| Preferred Stock Dividends And Other Adjustments | $1.1M | $867.0K | |||||
| Deferred Preclinical Charges Included In Prepaid Expenses And Other Current Assets | $349.0K | $420.0K | $503.0K | ||||
| Related Party Service Fee Payable | $9.0K | $99.0K | |||||
| Repayments Of Other Short Term Debt | $1.4M | $160.0K | |||||
| Amortization Of Debt Discount Premium | $488.0K | $186.0K | |||||
| Loss On Debt Conversion | -$431.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $37.5M | $16.4M | $11.3M | -$27.9M | -$14.8M | -$24.5M | $3.4M | -$19.4M | -$15.1M | $4.6M | $9.9M | $13.2M | $19.0M | -$4.2M | -$3.4M | -$1.9M | -$1.3M | -$1.1M | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $42.7M | $22.3M | $19.8M | $32.3M | $41.8M | $48.9M | $14.3M | $18.8M | $24.3M | $7.0M | $10.6M | $13.6M | $18.0M | $1.0K | $147.0K | $63.0K | $1.0K | |||
| Retained Earnings Accumulated Deficit | -$113.2M | -$107.1M | -$100.7M | -$79.7M | -$75.6M | -$85.5M | -$56.7M | -$52.4M | -$48.6M | -$28.7M | -$23.1M | -$19.5M | -$13.2M | -$8.0M | ||||||
| Liabilities Current | $13.1M | $13.6M | $16.7M | $10.5M | $13.1M | $30.3M | $15.5M | $15.4M | $16.0M | $5.5M | $2.8M | $2.4M | $785.0K | $5.1M | ||||||
| Liabilities And Stockholders Equity | $50.6M | $30.0M | $27.9M | $38.6M | $44.7M | $52.4M | $19.4M | $22.9M | $27.2M | $10.2M | $12.8M | $15.8M | $19.8M | $913.0K | ||||||
| Liabilities | $13.1M | $13.6M | $16.7M | $10.7M | $13.4M | $30.7M | $16.0M | $16.1M | $16.7M | $5.6M | $2.9M | $2.5M | $785.0K | $5.1M | ||||||
| Common Stock Value | $21.0K | $122.0K | $120.0K | $98.0K | $43.0K | $37.0K | $35.0K | $15.0K | $15.0K | $15.0K | $15.0K | $15.0K | $15.0K | $9.0K | ||||||
| Assets Current | $50.3M | $29.5M | $27.3M | $37.7M | $44.1M | $51.7M | $18.6M | $21.9M | $26.2M | $10.0M | $12.6M | $15.5M | $19.8M | $913.0K | ||||||
| Assets | $50.6M | $30.0M | $27.9M | $38.6M | $44.7M | $52.4M | $19.4M | $22.9M | $27.2M | $10.2M | $12.8M | $15.8M | $19.8M | $913.0K | ||||||
| Accounts Payable Current | $957.0K | $775.0K | $1.4M | $548.0K | $1.5M | $1.2M | $1.1M | $503.0K | $790.0K | $2.3M | $747.0K | $589.0K | $49.0K | $357.0K | ||||||
| Accrued Liabilities Current | $2.8M | $2.2M | $4.1M | $3.0M | $3.1M | $3.6M | $2.5M | $1.7M | $1.7M | $3.1M | $1.9M | $1.7M | $633.0K | $658.0K | $168.0K | |||||
| Property Plant And Equipment Net | $75.0K | $83.0K | $83.0K | $61.0K | $43.0K | $23.0K | $28.0K | $30.0K | $21.0K | $24.0K | $26.0K | $28.0K | ||||||||
| Operating Lease Right Of Use Asset | $249.0K | $386.0K | $518.0K | $772.0K | $604.0K | $686.0K | $845.0K | $923.0K | $997.0K | $191.0K | $230.0K | $268.0K | ||||||||
| Operating Lease Liability Current | $265.0K | $409.0K | $548.0K | $542.0K | $360.0K | $343.0K | $314.0K | $303.0K | $276.0K | $165.0K | $160.0K | $155.0K | ||||||||
| Operating Lease Right Of Use Asset Amortization Expense | $127.0K | $275.0K | $43.0K | $37.0K | ||||||||||||||||
| Prepaid Expense And Other Assets Current | $7.6M | $7.2M | $7.6M | $5.4M | $2.3M | $2.7M | $4.2M | $3.1M | $1.7M | $10.0K | ||||||||||
| Cash And Cash Equivalents At Carrying Value | $42.7M | $22.3M | $19.8M | $14.3M | $18.8M | $24.3M | $455.0K | $7.0M | $10.6M | $13.6M | $18.0M | $1.0K | ||||||||
| Operating Lease Liability Noncurrent | $265.0K | $274.0K | $372.0K | $552.0K | $634.0K | $715.0K | $29.0K | $72.0K | $114.0K | |||||||||||
| Deferred Insurance Charges Included In Prepaid Expenses And Other Current Assets | $142.0K | $146.0K | $121.0K | $275.0K | ||||||||||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$6.4M | $39.2M | $23.9M | |||||||||||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $23.9M | -$3.0M | $147.0K | |||||||||||||||||
| Preferred Stock Dividends And Other Adjustments | $887.0K | $208.0K | $72.0K | $603.0K | $192.0K | |||||||||||||||
| Deferred Preclinical Charges Included In Prepaid Expenses And Other Current Assets | $290.0K | $86.0K | $121.0K | |||||||||||||||||
| Related Party Service Fee Payable | $9.0K | |||||||||||||||||||
| Repayments Of Other Short Term Debt | $460.0K | |||||||||||||||||||
| Amortization Of Debt Discount Premium | $197.0K | |||||||||||||||||||
| Loss On Debt Conversion | -$4.2M | -$3.5M | -$431.0K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Share-Based Compensation * | $2.6M | $2.4M | $1.8M | $1.0M | $966.0K | $232.0K |
| Net Cash Provided By Used In Operating Activities | -$31.3M | -$28.6M | -$18.3M | -$15.7M | -$5.8M | -$1.5M |
| Increase Decrease In Accounts Payable And Accrued Liabilities | -$2.5M | $790.0K | $1.3M | $1.3M | $1.2M | -$68.0K |
| Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition | $2.6M | $2.4M | $1.8M | $1.0M | ||
| Net Cash Provided By Used In Financing Activities | $46.5M | $45.1M | $27.5M | -$471.0K | $22.4M | $1.4M |
| Net Cash Provided By Used In Investing Activities | -$12.1M | -$72.0K | -$12.0K | -$2.0K | -$29.0K | |
| Increase Decrease In Operating Lease Liability | -$565.0K | -$397.0K | -$252.0K | -$151.0K | -$12.0K | |
| Payments To Acquire Property Plant And Equipment | $24.0K | $72.0K | $12.0K | $2.0K | $29.0K | |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $2.9M | $820.0K | $1.1M | -$62.0K | ||
| Increase Decrease In Prepaid Expenses Other | $1.3M | -$1.0K | ||||
| Proceeds From Short Term Debt | $248.0K | $271.0K | ||||
| Proceeds From Issuance Of Preferred Stock And Preference Stock | $50.0M | |||||
| Proceeds From Issuance Of Other Long Term Debt | $1.1M | $1.3M | ||||
| Increase Decrease In Other Current Assets | -$62.0K | $1.3M | ||||
| Increase Decrease In Deferred Revenue | $146.0K | $396.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share-Based Compensation * | $563.0K | $522.0K | $929.0K | $144.0K | $266.0K | $294.0K | $290.0K | $239.0K | $294.0K | $202.0K | $71.0K | $60.0K | $31.0K | |||||
| Net Cash Provided By Used In Operating Activities | -$8.9M | -$6.5M | -$3.9M | -$3.0M | -$673.0K | |||||||||||||
| Increase Decrease In Accounts Payable And Accrued Liabilities | $791.0K | $822.0K | -$193.0K | $24.0K | -$83.0K | |||||||||||||
| Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition | $729.0K | $571.0K | $563.0K | $605.0K | $641.0K | $522.0K | $929.0K | $144.0K | $144.0K | $266.0K | $294.0K | $290.0K | ||||||
| Net Cash Provided By Used In Financing Activities | $2.5M | $45.7M | $27.8M | $820.0K | ||||||||||||||
| Net Cash Provided By Used In Investing Activities | -$16.0K | -$6.0K | -$2.0K | |||||||||||||||
| Increase Decrease In Operating Lease Liability | -$133.0K | -$273.0K | -$54.0K | -$36.0K | ||||||||||||||
| Payments To Acquire Property Plant And Equipment | $16.0K | $6.0K | $2.0K | |||||||||||||||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $2.5M | -$1.3M | -$338.0K | |||||||||||||||
| Increase Decrease In Prepaid Expenses Other | -$263.0K | $80.0K | ||||||||||||||||
| Proceeds From Short Term Debt | $151.0K | |||||||||||||||||
| Proceeds From Issuance Of Preferred Stock And Preference Stock | $50.0M | $30.2M | ||||||||||||||||
| Proceeds From Issuance Of Other Long Term Debt | $1.0M | |||||||||||||||||
| Increase Decrease In Other Current Assets | -$338.0K | -$263.0K | ||||||||||||||||
| Increase Decrease In Deferred Revenue | $37.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Diluted EPS * | -$1.67 | -$5.65 | -$1.28 | -$1.20 | -$0.86 | |
| Weighted Average Number Of Shares Outstanding Basic | 15.9M | 6.7M | 24.5M | 15.1M | 11.7M | 8.5M |
| Earnings Per Share Basic | $-1.67 | $-5.65 | $-1.28 | $-1.20 | $-0.86 | $-0.27 |
| Weighted Average Number Of Diluted Shares Outstanding | 15.9M | 6.7M | 24.5M | 15.1M | 11.7M | |
| Common Stock Shares Authorized | 400.0M | 400.0M | 200.0M | 200.0M | 200.0M | 200.0M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common Stock Shares Outstanding | 22.1M | 11.4M | 34.8M | 15.2M | 15.0M | 8.5M |
| Common Stock Shares Issued | 22.1M | 11.4M | 34.8M | 15.2M | 15.0M | 8.5M |
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | ||||
| Preferred Stock Shares Issued | 0.00 | 0.00 | ||||
| Weighted Average Number Of Share Outstanding Basic And Diluted |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$0.33 | -$0.52 | -$0.05 | -$0.46 | -$1.50 | -$0.61 | -$0.13 | -$0.29 | -$0.97 | -$0.37 | -$0.24 | -$0.24 | -$0.37 | -$0.13 | -$0.08 | -$0.04 | ||||
| Weighted Average Number Of Shares Outstanding Basic | 18.1M | 12.3M | 116.8M | 8.9M | 3.8M | 34.9M | 32.6M | 15.2M | 15.2M | 15.1M | 15.0M | 15.0M | 14.2M | 8.8M | 8.6M | |||||
| Earnings Per Share Basic | $-0.33 | $-0.52 | $-0.46 | $0.80 | $-0.61 | $-0.13 | $-0.29 | $-0.97 | $-0.37 | $-0.24 | $-0.24 | $-0.37 | $-0.13 | $-0.11 | ||||||
| Weighted Average Number Of Diluted Shares Outstanding | 18.1M | 12.3M | 123.8M | 8.9M | 9.4M | 34.9M | 32.6M | 15.2M | 15.2M | 15.1M | 15.0M | 15.0M | 14.2M | 8.8M | ||||||
| Common Stock Shares Authorized | 400.0M | 400.0M | 400.0M | 400.0M | 400.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | ||||||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||
| Common Stock Shares Outstanding | 20.9M | 14.1M | 119.7M | 97.9M | 43.6M | 37.6M | 34.8M | 15.2M | 15.2M | 15.1M | 15.0M | 15.0M | 15.0M | 8.8M | ||||||
| Common Stock Shares Issued | 20.9M | 14.1M | 119.7M | 97.9M | 43.6M | 37.6M | 34.8M | 15.2M | 15.2M | 15.1M | 15.0M | 15.0M | 15.0M | 8.8M | ||||||
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 9.8M | 9.9M | 9.9M | 9.9M | 10.0M | 30.2K | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | |||||||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 30.2K | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||||
| Preferred Stock Shares Issued | 0.00 | 30.2K | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||||||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 14.2M | 8.8M | 8.5M | 8.5M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Stock Issued During Period Value Stock Options Exercised | $4.0K | $27.0K | $29.0K | $59.0K | ||
| Additional Paid In Capital | $158.0M | $108.7M | $60.7M | $33.5M | $32.4M | $3.2M |
| Fair Value Adjustment Of Warrants | -$2.0M | $5.8M | $10.3M | |||
| Depreciation | $34.0K | $22.0K | $9.0K | $7.0K | $1.0K | |
| Investment Income Interest | $1.0M | $1.3M | $615.0K | |||
| Warrants And Rights Outstanding | $16.9M | $18.9M | $13.1M | |||
| Stock Issued During Period Value New Issues | $45.2M | $524.0K | $11.0K | $142.0K | ||
| Stock Issued1 | $867.0K | $82.0K | ||||
| Payments On Financed Insurance Policies | $212.0K | $527.0K | $496.0K | |||
| Stock Issued During Period Shares Restricted Stock Award Gross | 2.5K | 1.2K | 1.0K | 1.0K | ||
| Interest Paid Net | $12.0K | $24.0K | $6.0K | |||
| Other Prepaid Expense Current | $1.8M | |||||
| Paid In Kind Interest | $139.0K | $53.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Issued During Period Value Stock Options Exercised | $1.0K | $2.0K | $7.0K | $7.0K | $7.0K | $7.0K | $8.0K | $7.0K | $14.0K | $6.0K | $31.0K | |||||||
| Additional Paid In Capital | $150.6M | $123.5M | $111.9M | $107.5M | $60.8M | $61.0M | $60.1M | $33.0M | $33.5M | $33.3M | $33.0M | $32.7M | $32.2M | $3.8M | ||||
| Fair Value Adjustment Of Warrants | -$1.1M | -$374.0K | -$8.3M | -$1.8M | -$16.8M | $11.8M | -$1.4M | -$282.0K | $10.4M | |||||||||
| Depreciation | $8.0K | $9.0K | $2.0K | $2.0K | ||||||||||||||
| Investment Income Interest | $279.0K | $155.0K | $226.0K | $416.0K | $462.0K | $69.0K | $227.0K | $234.0K | $14.0K | |||||||||
| Warrants And Rights Outstanding | $9.1M | $10.2M | $10.6M | $6.4M | $8.1M | $24.9M | $11.5M | |||||||||||
| Stock Issued During Period Value New Issues | $26.3M | $9.5M | $2.7M | $22.3M | $92.0K | $50.0K | ||||||||||||
| Stock Issued1 | $208.0K | $192.0K | $72.0K | |||||||||||||||
| Payments On Financed Insurance Policies | $160.0K | $496.0K | ||||||||||||||||
| Stock Issued During Period Shares Restricted Stock Award Gross | ||||||||||||||||||
| Interest Paid Net | $6.0K | $5.0K | ||||||||||||||||
| Other Prepaid Expense Current | $1.9M | $2.2M | $3.0M | $2.0M | $1.8M | $58.0K | $38.0K | |||||||||||
| Paid In Kind Interest | $56.0K |
Most recent annual filing with the SEC: March 30, 2026
Data sourced from SEC EDGAR public filings as of August 6, 2026.